MX366985B - Sales derivadas de bencisoxazol. - Google Patents
Sales derivadas de bencisoxazol.Info
- Publication number
- MX366985B MX366985B MX2016014948A MX2016014948A MX366985B MX 366985 B MX366985 B MX 366985B MX 2016014948 A MX2016014948 A MX 2016014948A MX 2016014948 A MX2016014948 A MX 2016014948A MX 366985 B MX366985 B MX 366985B
- Authority
- MX
- Mexico
- Prior art keywords
- salt
- derivative salt
- benzisoxazole derivative
- relates
- forms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a novedosas sales del ácido 4-{[4-({[4-(2,2,2-trifluoroetoxi)-1,2-bencisoxazol-3-il]oxi}metil )piperidin-1-il]metil}tetrahidro-2H-piran-4-carboxílico. Más particularmente, la invención se refiere a formas de sal (sal con HCl, sal con HBr, sal p-toluensulfonato y sal etanodisulfonato), y a procesos para la preparación de, composiciones que las contienen y a los usos de, tales formas de sal.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462000687P | 2014-05-20 | 2014-05-20 | |
PCT/JP2015/002528 WO2015178020A1 (en) | 2014-05-20 | 2015-05-20 | Benzisoxazole derivative salt |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2016014948A MX2016014948A (es) | 2017-05-25 |
MX366985B true MX366985B (es) | 2019-08-01 |
Family
ID=54553701
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016014948A MX366985B (es) | 2014-05-20 | 2015-05-20 | Sales derivadas de bencisoxazol. |
Country Status (13)
Country | Link |
---|---|
US (1) | US9988370B2 (es) |
EP (1) | EP3145926B1 (es) |
JP (1) | JP6572414B2 (es) |
KR (1) | KR102471082B1 (es) |
CN (2) | CN108329305A (es) |
BR (1) | BR112016024213A2 (es) |
CA (1) | CA2944982C (es) |
ES (1) | ES2747989T3 (es) |
HK (2) | HK1231483A1 (es) |
MX (1) | MX366985B (es) |
RU (1) | RU2679619C2 (es) |
TW (1) | TWI672300B (es) |
WO (1) | WO2015178020A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102471082B1 (ko) * | 2014-05-20 | 2022-11-25 | 라퀄리아 파마 인코포레이티드 | 벤즈이소옥사졸 유도체염 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
AU2003265681A1 (en) * | 2002-08-29 | 2004-03-19 | Merck And Co., Inc. | Indoles having anti-diabetic activity |
CA2598516C (en) * | 2005-02-25 | 2010-05-11 | Pfizer Inc. | Benzisoxazole derivatives |
WO2011101774A1 (en) | 2010-02-16 | 2011-08-25 | Pfizer Inc. | (r)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol, a partial agonist of 5-ht4 receptors |
RU2597766C2 (ru) | 2011-03-23 | 2016-09-20 | Раквалиа Фарма Инк. | Агонист рецептора 5-нт4 в качестве прокинетического агента |
EP2710002B1 (en) * | 2011-05-18 | 2017-03-01 | RaQualia Pharma Inc | Polymorph form of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2h-pyran-4-carboxylic acid |
KR102471082B1 (ko) * | 2014-05-20 | 2022-11-25 | 라퀄리아 파마 인코포레이티드 | 벤즈이소옥사졸 유도체염 |
-
2015
- 2015-05-20 KR KR1020167030272A patent/KR102471082B1/ko active IP Right Grant
- 2015-05-20 CA CA2944982A patent/CA2944982C/en active Active
- 2015-05-20 JP JP2016568452A patent/JP6572414B2/ja active Active
- 2015-05-20 TW TW104116120A patent/TWI672300B/zh active
- 2015-05-20 ES ES15796887T patent/ES2747989T3/es active Active
- 2015-05-20 EP EP15796887.6A patent/EP3145926B1/en active Active
- 2015-05-20 US US15/312,440 patent/US9988370B2/en active Active
- 2015-05-20 WO PCT/JP2015/002528 patent/WO2015178020A1/en active Application Filing
- 2015-05-20 CN CN201810233844.9A patent/CN108329305A/zh active Pending
- 2015-05-20 CN CN201580022256.5A patent/CN107074837B/zh active Active
- 2015-05-20 MX MX2016014948A patent/MX366985B/es active IP Right Grant
- 2015-05-20 BR BR112016024213A patent/BR112016024213A2/pt not_active IP Right Cessation
- 2015-05-20 RU RU2016149650A patent/RU2679619C2/ru active
-
2017
- 2017-05-24 HK HK17105284.5A patent/HK1231483A1/zh unknown
-
2018
- 2018-08-23 HK HK18110880.2A patent/HK1251553A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
JP6572414B2 (ja) | 2019-09-11 |
RU2016149650A (ru) | 2018-06-20 |
US9988370B2 (en) | 2018-06-05 |
CA2944982C (en) | 2022-06-07 |
CN108329305A (zh) | 2018-07-27 |
CN107074837A (zh) | 2017-08-18 |
WO2015178020A1 (en) | 2015-11-26 |
TW201625602A (zh) | 2016-07-16 |
RU2016149650A3 (es) | 2018-11-30 |
ES2747989T3 (es) | 2020-03-12 |
EP3145926B1 (en) | 2019-07-03 |
MX2016014948A (es) | 2017-05-25 |
US20170081318A1 (en) | 2017-03-23 |
HK1231483A1 (zh) | 2017-12-22 |
BR112016024213A2 (pt) | 2017-08-15 |
HK1251553A1 (zh) | 2019-02-01 |
EP3145926A4 (en) | 2017-12-27 |
JP2017515868A (ja) | 2017-06-15 |
KR102471082B1 (ko) | 2022-11-25 |
CA2944982A1 (en) | 2015-11-26 |
RU2679619C2 (ru) | 2019-02-12 |
TWI672300B (zh) | 2019-09-21 |
EP3145926A1 (en) | 2017-03-29 |
KR20170007737A (ko) | 2017-01-20 |
CN107074837B (zh) | 2020-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2017002714A2 (es) | Ácido 4-(3-fluoro-3-(2-(5,6,7,8-tetrahidro-1,8-naftiridin-2-il)etil)pirrolidin-1-il)-3-(3-(2-metoxietoxi)fenil)butanoico, o una sal del mismo | |
PH12017501191A1 (en) | Quinazoline derivatives used to treat hiv | |
PH12016501440A1 (en) | Novel heterocyclic compounds | |
MD4807C1 (ro) | Derivaţi de pirimidiniloxi-benzen utilizaţi ca erbicide | |
MX2017004200A (es) | Compuestos de heteroarilo como inhibidores de tirosina-cinasa de bruton (btk) y usos de estos. | |
PH12016502378A1 (en) | Substituted dihydroisoquinolinone compounds | |
MD20160106A2 (ro) | Compuşi aril sau heteroaril biciclici condensaţi şi utilizarea acestora ca inhibitori IRAK4 | |
MX2017008518A (es) | Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih). | |
MX2016015565A (es) | Ciertos inhibidores de la proteina quinasa. | |
MX2018012085A (es) | Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119. | |
EA201791058A1 (ru) | Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4) | |
IN2014MU00675A (es) | ||
MX2016010272A (es) | Derivado de indolona sustituido por pirrol, metodo de preparacion del mismo, composicion que comprende el mismo y uso del mismo. | |
MX350024B (es) | Formas polimorfas del ácido 4-{[4-({[4-(2,2,2-trifluoroetoxi)-1,2- benzisoxazol-3-il]oxi}metil)piperidin-1-il]metil}-tetrahidro-2h-p iran-4-carboxílico. | |
BR112016021910A2 (pt) | Processo de preparação de 3-(3-(4-(1-aminociclobutil)fenil)-5-fenil-3h-imidazo[4,5-b]piridin-2-il)piridin-2-amina | |
EA201791396A1 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ | |
EA201791397A1 (ru) | СВЯЗАННЫЕ С ГЕТЕРОЦИКЛИЛАМИ ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ | |
MX366985B (es) | Sales derivadas de bencisoxazol. | |
MX353994B (es) | Formas polimorfas. | |
MX2020009412A (es) | Sales y polimorfos de un compuesto imidazopiridinil-aminopiridina sustituido. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |